Monday, February 18, 2013
As pricing pressures continue
to increase in Europe, pharma companies are starting to shrink their European
footprint with smaller commercial organizations and a narrower focus on key
products or specialty areas.
The sales numbers tell the
story: Across 10 pharma companies that have broken out their numbers, 2012
European drug sales were down $10.1 billion (11%) compared to 2011.